A Randomized, Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Trial Profile

A Randomized, Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2014

At a glance

  • Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Rilpivirine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 27 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jul 2013 Results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.
    • 22 Feb 2013 Planned End Date changed from 1 Jan 2013 to 1 Nov 2013, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top